Literature DB >> 9502190

Inhibitory effects of hyperglycaemia on fed jejunal motility: potential role of hyperinsulinaemia.

M M Byrne1, K Pluntke, U Wank, J Schirra, R Arnold, B Göke, M Katschinski.   

Abstract

BACKGROUND: Acute hyperglycaemia is known to inhibit jejunal interdigestive motility. This study was undertaken to establish the effects of hyperglycaemia on fed jejunal motility and small intestinal transit time, and to establish if the effects of hyperglycaemia are mediated in part by hyperinsulinaemia.
METHODS: Nine healthy male volunteers were studied in random order using three experimental conditions: (a) euglycaemic clamp [glucose 5 mmol L(-1)]; (b) hyperglycaemic clamp [glucose 15 mmol L(-1)]; and (c) euglycaemic hyperinsulinaemic clamp [glucose 5 mmol L(-l)]. Fed jejunal motility was induced by an intrajejunal perfusion of lipid (Lipofundin medium-chained triglyceride 10%) at 1.5 mL min(-1) [1.5 kcal min(-1)] for 180 min through the most proximal port of a manometry catheter (eight ports spaced at 2-cm intervals) located just distal to the ligament of Treitz. One minute after starting the lipid perfusion, 15 g of lactulose dissolved in 20 mL of tap water was infused. Small intestinal transit time was measured by the hydrogen breath test.
RESULTS: Acute hyperglycaemia reduced the total number of jejunal contractions and progradely propagated contractions, the motility index (P < 0.05) and the mean amplitude of contractions and delayed intestinal transit time. Hyperinsulinaemia reduced the total number of jejunal contractions, motility index (P < 0.05) and intestinal transit time.
CONCLUSIONS: Thus, hyperinsulinaemia may contribute to the inhibitory effects of hyperglycaemia on jejunal motility. In addition, this study demonstrated that intrajejunal infusion of lipid stimulates sustained glucagon-like peptide-1 release. In contrast to fat-induced gastric inhibitory polypeptide release, this glucagon-like peptide-1 release is not inhibited by exogenous or endogenous hyperinsulinaemia (P = 0.59).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9502190     DOI: 10.1046/j.1365-2362.1998.00240.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  7 in total

Review 1.  Small bowel review: normal physiology part 2.

Authors:  A B Thomson; M Keelan; A Thiesen; M T Clandinin; M Ropeleski; G E Wild
Journal:  Dig Dis Sci       Date:  2001-12       Impact factor: 3.199

2.  Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans.

Authors:  J Schirra; P Houck; U Wank; R Arnold; B Göke; M Katschinski
Journal:  Gut       Date:  2000-05       Impact factor: 23.059

3.  Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans.

Authors:  J Schirra; U Wank; R Arnold; B Göke; M Katschinski
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

4.  Effect of duodenal glucose and acute hyperglycemia on rectal perception and compliance in response to tension-controlled rectal distension in healthy humans.

Authors:  Ana Cristina Hernando-Harder; Manfred Vincenz Singer; Hermann Harder
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.199

5.  Multiple intestinal intussusceptions as a complication of severe hyperglycemia in a patient with diabetic ketoacidosis.

Authors:  Pooja Raghavan; Jeffrey Salon; Dhyan Rajan
Journal:  Case Rep Endocrinol       Date:  2012-09-26

6.  Glucose absorption in gestational diabetes mellitus during an oral glucose tolerance test.

Authors:  Christian Anderwald; Andrea Tura; Yvonne Winhofer; Michael Krebs; Christine Winzer; Martin G Bischof; Anton Luger; Giovanni Pacini; Alexandra Kautzky-Willer
Journal:  Diabetes Care       Date:  2011-05-20       Impact factor: 19.112

7.  Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies.

Authors:  Omar S Al-Attas; Nasser M Al-Daghri; Khalid Al-Rubeaan; Nancy F da Silva; Shaun L Sabico; Sudhesh Kumar; Philip G McTernan; Alison L Harte
Journal:  Cardiovasc Diabetol       Date:  2009-04-15       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.